Table 2 Number of patients with or without pulmonary malignancy and the presence of onconeuronal, antineuronal, and welldefined onconeuronal antibodies.
Primary pulmonary malignancy | No primary pulmonary malignancy identified | |
|---|---|---|
Onconeuronal and antineuronal | 5 | 6 |
antibodies (n = 11) | (45%) | (54%) |
No onconeuronal and antineuronal | 6 | 4 |
antibodies present (n = 10) | (60%) | (40%) |
Well-defined onconeuronal | 3 | 2 |
antibodies (n = 5) | (60%) | (40%) |
No well-defined onconeuronal | 8 | 8 |
antibodies present (n = 16) | (50%) | (50%) |